中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (31): 5805-5808.doi: 10.3969/j.issn.1673-8225.2011.31.025

• 移植与免疫 transplantation and Immunology • 上一篇    下一篇

同种异体肢体移植中他克莫司的应用剂量

尚  剑，刘  伟，韩昕光，凌晓东，苏  俭   

  1. 哈尔滨医科大学第一附属医院骨科，黑龙江省哈尔滨市， 150001
  • 收稿日期:2011-01-21 修回日期:2011-06-30 出版日期:2011-07-30 发布日期:2011-07-30
  • 通讯作者: 韩昕光，博士，主治医师，哈尔滨医科大学附属第一医院骨科，黑龙江省哈尔滨市 150001 Hxg9908@163.com
  • 作者简介:尚剑☆，男，1967年生，哈尔滨市人，汉族，2010年哈尔滨医科大学毕业，博士，教授，主任医师，主要从事骨外科方面的研究。 shj1616@sina.com
  • 基金资助:

    黑龙江教育厅科学技术研究项目(10531108)。

Tacrolimus application dose in limb allograft transplantation

Shang Jian, Liu Wei, Han Xin-guang, Ling Xiao-dong, Su Jian   

  1. Department of Orthopedics, First Affiliated Hospital of Harbin Medical University, Harbin  150001, Heilongjiang Province, China
  • Received:2011-01-21 Revised:2011-06-30 Online:2011-07-30 Published:2011-07-30
  • Contact: Han Xin-guang, Doctor, Attending physician, Department of Orthopedics, First Affiliated Hospital of Harbin Medical university, Harbin 150001, Heilongjiang Province, China Hxg9908@163.com
  • About author:Shang Jian☆, Doctor, Professor, Chief physician, Department of Orthopedics, First Affiliated Hospital of Harbin Medical university, Harbin 150001, Heilongjiang Province, China shj1616@sina.com
  • Supported by:

    Science and Technology Research Program of Education Department of Heilongjiang Province, No. 10531108*

PDF

275

摘要：

背景：他克莫司应用于同种异体肝移植的免疫耐受已多见报道。
目的：探索他克莫司在异体肢体移植时的最佳应用剂量。
方法：建立同种异体肢体移植大鼠模型，移植造模后设立给予不同他克莫司剂量的0.5，1，2 mg/(kg•d)组及对照组，对大鼠进行大体观察、组织学、淋巴细胞亚群测定。
结果与结论：移植后出现排斥反应的时间分别是对照组(3.43±0.79) d、0.5 mg/(kg•d)组(5.68±0.97) d、1 mg/(kg•d)组(9.13±1.17) d、2 mg/(kg•d) 组(9.61±2.38) d，排斥反应的病理分级4组分别为(2.61±0.38)，(1.57±0.43)，(0.85±0.24)，(0.71±0.19)级。移植后各给药组CD4+、CD8+检测值均明显下降，CD4/CD8比值轻度增加或在正常值范围内；对照组CD4+、CD8+无明显变化，CD4/CD8比值明显增加。提示，他克莫司的应用剂量在1 mg/(kg•d)时就能达到理想的抑制免疫排斥反应，提高用量后意义不大。

关键词: 他克莫司, 同种异体肢体移植, 造模, 剂量, 排斥反应

Abstract:

BACKGROUND: Tacrolimus (FK506) is widely used in human organ transplantation and prolongs allograft survival in several animal models, yet there is still no consistent standard in current clinical application.
OBJECTIVE: To investigate the optimal application dose of FK506 in limb allograft rats.
METHODS: Sixty rat models of hind limb allograft were randomly divided into three groups (A, B and C) and daily received FK506 0.5, 1, and 2 mg/kg respectively. Twenty untreated allograft rats served as the control group. Gross observation, morphological change observation and T lymphocyte subsets analysis were performed to evaluate the efficiency of FK506.
RESULTS AND CONCLUSION: The occurrence time of rejection was assessed as follows: control group (3.43±0.79) days, A group (5.68±0.97) days, B group (9.13±1.17) days, and C group (9.61±2.38) days. The skin pathological grade of limb allograft rejection was grade (2.61±0.38) in the control group, grade (1.57±0.43) in the A group, grade (0.85±0.24) in the B group, and grade (0.71±0.19) in the C group. In the FK 506-treated allograft groups, the value of CD4+ and CD8+ was significantly decreased and CD4/CD8 slightly increased or kept normal condition. In the control group, CD4+ and CD8+ remained unchanged and CD4/CD8 increased significantly. FK 506 prolonged hind limb allograft survival and prevented rejection compared with untreated controls. A dose of 1 mg/kg per day could achieve the ideal effect; however, increasing the dose did not improve effect significantly.

中图分类号: